We are live on ! Find out more
MNPR icon

Monopar Therapeutics

56 hedge funds and large institutions have $354M invested in Monopar Therapeutics in 2025 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

433% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 3

213% more capital invested

Capital invested by funds: $113M → $354M (+$241M)

30% more funds holding

Funds holding: 4356 (+13)

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

18.33% more ownership

Funds ownership: 51.94%70.28% (+18%)

Holders
56
Holders Change
+13
Holders Change %
+30.23%
% of All Funds
0.73%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
16
Increased
18
Reduced
15
Closed
3
Calls
Puts
Net Calls
Net Calls Change

MNPR Hedge Fund Activity: Q3 2025 in Review

56 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2025, worth a combined $354M — up 213% from $113M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new MNPR positions and 3 closed out — a net gain of 13 holders — while 18 added to existing stakes and 15 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $10.3M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $3.72M sold.

  • 56 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2025, up from 43 in Q2 2025.
  • Funds reported $354M of Monopar Therapeutics stock for Q3 2025, up 213% quarter-over-quarter.
  • 16 funds opened new Monopar Therapeutics positions in Q3 2025 and 3 closed out, a net change of +13 holders.
  • The largest Monopar Therapeutics buyer in Q3 2025 was Wellington Management Group, an estimated $10.3M added.
  • The largest Monopar Therapeutics seller in Q3 2025 was Point72 Asset Management, an estimated $3.72M sold.

Based on aggregated 13F filings for Q3 2025.